ZA932445B - Novel antibodies for treatment and prevention of respiratory syncytial virus infection in animals and man - Google Patents
Novel antibodies for treatment and prevention of respiratory syncytial virus infection in animals and manInfo
- Publication number
- ZA932445B ZA932445B ZA932445A ZA932445A ZA932445B ZA 932445 B ZA932445 B ZA 932445B ZA 932445 A ZA932445 A ZA 932445A ZA 932445 A ZA932445 A ZA 932445A ZA 932445 B ZA932445 B ZA 932445B
- Authority
- ZA
- South Africa
- Prior art keywords
- man
- animals
- prevention
- treatment
- virus infection
- Prior art date
Links
- 241001465754 Metazoa Species 0.000 title 1
- 206010061603 Respiratory syncytial virus infection Diseases 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- 208000030925 respiratory syncytial virus infectious disease Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Plant Pathology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Physics & Mathematics (AREA)
- Pulmonology (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB929207479A GB9207479D0 (en) | 1992-04-06 | 1992-04-06 | Novel antibodies for treatment and prevention of respiratory syncytial virus infection in animals and man |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA932445B true ZA932445B (en) | 1995-01-05 |
Family
ID=10713521
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA932445A ZA932445B (en) | 1992-04-06 | 1993-04-05 | Novel antibodies for treatment and prevention of respiratory syncytial virus infection in animals and man |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP0636182A1 (fr) |
JP (1) | JPH07508401A (fr) |
KR (1) | KR950701386A (fr) |
AU (1) | AU679440B2 (fr) |
CA (1) | CA2133662A1 (fr) |
GB (1) | GB9207479D0 (fr) |
NZ (1) | NZ251405A (fr) |
WO (1) | WO1993020210A1 (fr) |
ZA (1) | ZA932445B (fr) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5824307A (en) | 1991-12-23 | 1998-10-20 | Medimmune, Inc. | Human-murine chimeric antibodies against respiratory syncytial virus |
US6258529B1 (en) * | 1994-12-01 | 2001-07-10 | Oravax, Inc. | PCR amplification of rearranged genomic variable regions of immunoglobulin genes |
US7153508B2 (en) | 1995-06-07 | 2006-12-26 | Biogen Idec Inc. | Treatment of B cell lymphoma using anti-CD80 antibodies that do not inhibit the binding of CD80 to CTLA-4 |
US5811524A (en) * | 1995-06-07 | 1998-09-22 | Idec Pharmaceuticals Corporation | Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof |
US7175847B1 (en) | 1995-06-07 | 2007-02-13 | Biogen Idec Inc. | Treating intestinal inflammation with anti-CD80 antibodies that do not inhibit CD80 binding to CTLA-4 |
EP0851924A1 (fr) | 1995-09-18 | 1998-07-08 | Intracel Corporation | Anticorps monoclonaux neutralisants diriges contre le virus respiratorie syncytial |
FR2758331B1 (fr) * | 1997-01-14 | 1999-03-05 | Univ Bourgogne | Nouveaux moyens pour le diagnostic, la prevention et le traitement vis-a-vis de contaminations ou d'infections par des virus a tropisme muqueux |
US6160099A (en) * | 1998-11-24 | 2000-12-12 | Jonak; Zdenka Ludmila | Anti-human αv β3 and αv β5 antibodies |
CA2409689A1 (fr) * | 2000-05-03 | 2001-11-08 | Medimmune, Inc. | Polytherapie de maladies respiratoires utilisant des anticorps |
AU2001263443A1 (en) * | 2000-05-25 | 2001-12-03 | Med Immune, Inc. | F-protein epitope-based vaccine for respiratory syncytial virus infection |
US7132100B2 (en) | 2002-06-14 | 2006-11-07 | Medimmune, Inc. | Stabilized liquid anti-RSV antibody formulations |
TW200636064A (en) * | 2004-10-28 | 2006-10-16 | Centocor Inc | Anti-respiratory syncytial virus antibodies, antigens and uses thereof |
EP1997830A1 (fr) | 2007-06-01 | 2008-12-03 | AIMM Therapeutics B.V. | Molécules à liaison spécifiques RSV et leur moyen de fabrication |
US8568726B2 (en) | 2009-10-06 | 2013-10-29 | Medimmune Limited | RSV specific binding molecule |
ES2699648T3 (es) | 2010-09-09 | 2019-02-12 | Pfizer | Moléculas de unión a 4-1BB |
FR2970968A1 (fr) * | 2011-02-01 | 2012-08-03 | Isp Investments Inc | Nouveaux peptides intervenant dans la voie de signalisation scf c-kit et compositions les comprenant |
US9364414B2 (en) | 2011-02-01 | 2016-06-14 | Isp Investments Inc. | Method to protect skin from ultraviolet radiation using novel peptides involved in the improvement of microparasol organization in keratinocytes |
AU2013208003B2 (en) | 2012-01-09 | 2017-12-14 | The Scripps Research Institute | Ultralong complementarity determining regions and uses thereof |
US20150011431A1 (en) | 2012-01-09 | 2015-01-08 | The Scripps Research Institute | Humanized antibodies |
CN105073781A (zh) | 2013-01-11 | 2015-11-18 | 加州生物医学研究所 | 牛融合抗体 |
WO2015010100A2 (fr) * | 2013-07-18 | 2015-01-22 | Fabrus, Inc. | Anticorps humanisés comprenant des régions déterminant la complémentarité ultralongues |
JO3555B1 (ar) | 2015-10-29 | 2020-07-05 | Merck Sharp & Dohme | جسم مضاد يبطل فعالية فيروس الالتهاب الرئوي البشري |
CN112912394B (zh) * | 2018-09-03 | 2024-04-16 | 智利天主教教皇大学 | 针对hrsv的n抗原的单抗,可用于治疗感染、其检测和诊断 |
AU2021399453A1 (en) * | 2020-12-18 | 2023-07-27 | Zhuhai Trinomab Pharmaceutical Co., Ltd. | Respiratory syncytial virus-specific binding molecule |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE85622T1 (de) * | 1987-12-23 | 1993-02-15 | Upjohn Co | Chimarenglykoproteine, enthaltend immunogene segmente des humanen respiratorischen synzytialvirus. |
AU644210B2 (en) * | 1990-07-19 | 1993-12-02 | United States of America, as represented by the Secretary, U.S. Department of Commerce, The | Improved immunotherapeutic method of preventing or treating viral respiratory tract disease |
GB9019812D0 (en) * | 1990-09-11 | 1990-10-24 | Scotgen Ltd | Novel antibodies for treatment and prevention of infection in animals and man |
AU686113B2 (en) * | 1992-09-16 | 1998-02-05 | Scripps Research Institute, The | Human neutralizing monoclonal antibodies to respiratory syncytial virus |
WO1994017105A1 (fr) * | 1993-01-29 | 1994-08-04 | Medimmune, Inc. | Anticorps chimeres d'humain/de murin utilises contre le virus syncytial respiratoire |
-
1992
- 1992-04-06 GB GB929207479A patent/GB9207479D0/en active Pending
-
1993
- 1993-04-05 ZA ZA932445A patent/ZA932445B/xx unknown
- 1993-04-06 AU AU39000/93A patent/AU679440B2/en not_active Ceased
- 1993-04-06 WO PCT/GB1993/000725 patent/WO1993020210A1/fr not_active Application Discontinuation
- 1993-04-06 CA CA002133662A patent/CA2133662A1/fr not_active Abandoned
- 1993-04-06 KR KR1019940703584A patent/KR950701386A/ko not_active Application Discontinuation
- 1993-04-06 EP EP93908006A patent/EP0636182A1/fr not_active Withdrawn
- 1993-04-06 NZ NZ251405A patent/NZ251405A/en unknown
- 1993-04-06 JP JP5517272A patent/JPH07508401A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
JPH07508401A (ja) | 1995-09-21 |
AU679440B2 (en) | 1997-07-03 |
CA2133662A1 (fr) | 1993-10-14 |
WO1993020210A1 (fr) | 1993-10-14 |
KR950701386A (ko) | 1995-03-23 |
GB9207479D0 (en) | 1992-05-20 |
AU3900093A (en) | 1993-11-08 |
EP0636182A1 (fr) | 1995-02-01 |
NZ251405A (en) | 1997-09-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB9207479D0 (en) | Novel antibodies for treatment and prevention of respiratory syncytial virus infection in animals and man | |
GB9019812D0 (en) | Novel antibodies for treatment and prevention of infection in animals and man | |
IL132003A0 (en) | Antimicrobial prevention and treatment of human immundeficiency virus and other infectious diseases | |
EP0746322A4 (fr) | Traitement de la maladie d'alzheimer et modulation du systeme immunitaire a l'aide de delta5-androstenes | |
ZA951831B (en) | Vaccine for the prevention of respiratory and reproductive diseases of the pig | |
IL102092A0 (en) | Vaccine and treatment method for human immunodeficiency virus | |
LTIP863A (en) | Aminobenzodiazepines, process for preparing thereof and application for the treatment and prevention of viral diseases | |
EP0628056A4 (fr) | Immunoglobuline humaine dirigee pour la prevention et le traitement de staphylococcies. | |
IL105145A0 (en) | Recombinant human hiv-neutralizing monoclonal antibodies for prevention and treatment of hiv infection | |
AU7043694A (en) | Method of treatment and prevention of immune complex-induced lung injury | |
EP0382551A3 (en) | Prevention and treatment of herpes virus infections | |
ZA946489B (en) | Novel treatment of upper respiratory tract infections | |
HU9402816D0 (en) | Medicament for the treatment of airways inflammation and airways hyperresponsiveness | |
IL102815A0 (en) | Pharmaceutical compositions and method for the treatment of infection caused by the human immunodeficiency virus | |
GB9111885D0 (en) | Nerve growth factor for use in the prevention and treatment of viral infections | |
EP0655919A4 (fr) | Traitement d'infections virales chez l'homme. | |
HU913022D0 (en) | Fibroplast increasing factor for treating and preventing virus caused diseases | |
LTIP472A (en) | Composition for the treatment of infection and disease caused by hepatit b virus | |
AU4259193A (en) | Medicament for the gene-therapeutic treatment of human beings, animals and plants, especially to block virus multiplication and carcinogenes and process for producing the medicament | |
KR960006863B1 (en) | Pharmaceutical preparation for treatment of mastitis in animals and humans | |
GB9521008D0 (en) | Therapeutic treatment of viral infection in humans and animals | |
EG20171A (en) | Treatment of conditions and disease | |
IL102021A0 (en) | Protein-kinase inhibitors for the treatment of human and animal viral diseases | |
AU3981093A (en) | Preparation useful for prevention and treatment of intestinal infections in animals and human beings | |
ZA948741B (en) | Novel treatment of upper respiratory tract infections |